ArticleWorld journal of urology2025
The perks of combining extension and Gleason score of positive surgical margins after robot-assisted radical prostatectomy.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research on robot-assisted prostatectomy: a bibliometric and visualization analysis.Journal of robotic surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of positive surgical margins' (PSM) features in terms of cancer control outcomes is unclear. We aimed to test the association between PSM extension combined to highest Gleason score (GS) at margin and PSA persistence, biochemical recurrence (BCR) and clinical recurrence (CR) in prostate cancer (PCa) patients undergone robot-assisted radical prostatectomy (RARP). MATERIALS AND
methods2617 PCa patients treated with RARP at six European centers were stratified according to the PSM status and features, as follows): (a) negative SM; (b) focal PSM-GS 3; (c) extensive PSM-GS 3; (d) focal PSM-GS 4-5; (d) extensive PSM-GS 4-5. Multivariable logistic regression models addressed PSA persistence. Kaplan-Meier plots and multivariable Cox regression models addressed BCR and CR according to PSM status and features. Sensitivity analyses in patients with and without adverse pathological features were performed.
resultsOverall, 790 (30%) patients harbored PSM, 31% with GS 3 and 69% with GS 4-5, whereas 51% were focal and 49% were extensive. PSA persistence was independently predicted by "focal and extensive PSM-GS 4-5" combinations (odds ratios 1.57 and 2.17, respectively). BCR free survival at 36 months was 92 vs. 82% in respectively NSM and PSM patients. Only "extensive PSM-GS 4-5" combination was independently associated with BCR (hazard ratio [HR] 2.53). CR free survival at 36 months was 95 vs. 91% in respectively NSM and PSM patients. Only "extensive PSM-GS 4-5" combination was independently associated with CR (HR 1.45).
conclusionsPCa patients harboring "extensive PSM-GS 4-5" combination at final pathology have worse oncological outcomes compared to their NSM counterparts or PSM patients with less unfavorable PSM features. These findings may help to improve patients counselling, especially in case of additional treatments' decision making.
Indexed as
Identifiers
40783876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.